-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Downgrades Axsome Therapeutics to Equal-Weight, Raises Price Target to $204

Benzinga·01/08/2026 12:21:50
语音播报
Morgan Stanley analyst Sean Laaman downgrades Axsome Therapeutics (NASDAQ:AXSM) from Overweight to Equal-Weight and raises the price target from $196 to $204.